California News Observer: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on California News Observer.

Press releases published on October 5, 2026

Oct. 5, 2026

Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer

Indeterminate GlobeNewswire

Oct. 5, 2026

MAPS and International Alliance of Psychedelic Therapy Practitioners Announce Partnership to Advance Training for Psychedelic-Assisted Therapy

Indeterminate GlobeNewswire

Oct. 5, 2026

Magnite to Announce Third Quarter 2026 Financial Results on November 4, 2026

Indeterminate GlobeNewswire

Oct. 5, 2026

Kratos Secures More Than $100 Million in Contracts for Space and Cyber Mission Capabilities

Indeterminate GlobeNewswire

Oct. 5, 2026

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

Indeterminate GlobeNewswire

Oct. 5, 2026

Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study

Indeterminate GlobeNewswire

Oct. 5, 2026

Zscaler Collaborates with IBM and Red Hat to Protect Private Applications from Frontier AI-Powered Threats

Indeterminate GlobeNewswire

Oct. 5, 2026

Synoptic Data Secures Lead Subcontractor Role on NOAA’s Five-Year, $1.1B Ceiling National Mesonet Program Contract

Indeterminate GlobeNewswire

Oct. 5, 2026

Fractyl Health, Inc. Class Action Reminder – Robbins LLP Encourages GUTS Investors to Contact the Firm for Information About Their Rights

Indeterminate GlobeNewswire

Oct. 5, 2026

Zenflow Secures $52M Series D Financing and Announces Exclusive U.S. Distribution Partnership with Cook Medical

Indeterminate GlobeNewswire

Oct. 5, 2026

Robbins LLP Urges RYDE Investors with Large Losses to Contact the Firm for Information About the Class Action Against Ryde Group Ltd

Indeterminate GlobeNewswire

Oct. 5, 2026

Apriem Advisors' Chris Whitaker Named to Forbes Best-In-State Next-Gen Advisors List

Indeterminate GlobeNewswire

Oct. 5, 2026

BBP-418 Demonstrates Potential to Be Disease Modifying Therapy, Restoring Cardiac and Disease Markers to Unaffected Levels

Indeterminate GlobeNewswire

Oct. 5, 2026

Robbins LLP Reminds GDDY Investors of Securities Class Action and October 20, 2026 Lead Plaintiff Deadline

Indeterminate GlobeNewswire

Oct. 5, 2026

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences

Indeterminate GlobeNewswire

Oct. 5, 2026

Iridex Completes Relocation of Manufacturing Facility to San Jose, California

Indeterminate GlobeNewswire

Oct. 5, 2026

Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

Indeterminate GlobeNewswire

Oct. 5, 2026

Rezolute Announces FDA Recommendation to Hold a Pre-BLA Meeting as a Precursor to Submitting a Biologics License Application (BLA) for Congenital Hyperinsulinism

Indeterminate GlobeNewswire

Oct. 5, 2026

VisionWave Outlines Development of Autonomous Defense Ecosystem Across Tactical UAV and Counter-UAS Applications

Indeterminate GlobeNewswire

Oct. 5, 2026

Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate

Indeterminate GlobeNewswire